文献速递免疫规划传染病防控与疫情报告

ACE2抑制ELISA可作为SARS-CoV-2活病毒中和试验的有效替代方法

ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
PubMed 文献 · Vaccine · 2025-12-20

该研究以英国OCTAVE-DUO试验中103名免疫功能低下受试者的血清为样本,比较MSD ACE2抑制试验(ACE2i)与活病毒中和试验及总抗刺突IgG在 ancestral、Delta和Omicron刺突蛋白上的表现。结果显示所有试验均检测到疫苗接种后显著升高,但微量中和试验(MNA)和ACE2i对变异株尤其是Omicron的中和能力明显降低,而IgG试验未显示此差异。ACE2i可作为快速、可扩展、低生物安全等级的中和试验替代方法,支持疫苗许可和变异株监测。

要点

  • ACE2i与活病毒中和试验在检测疫苗接种后抗体升高上具有一致性。
  • MNA和ACE2i对Omicron等变异株的中和活性显著降低,而IgG试验未反映此变化。
  • ACE2i可作为低生物安全等级、快速可扩展的中和试验替代方法。

核心结论

  • ACE2抑制ELISA可作为SARS-CoV-2活病毒中和试验的有效替代方法,用于支持疫苗许可和变异株监测。

研究设计与样本

  • 研究分析了英国OCTAVE-DUO试验中103名免疫功能低下参与者的血清,在基线及加强针后21天进行检测。

主要发现

  • 所有试验均检测到疫苗接种后显著升高。
  • MNA和ACE2i对变异株尤其是Omicron的中和能力明显降低,而IgG试验未显示此降低。

临床怎么用

  • ACE2i可用于快速筛查和疫苗试验中中和抗体的替代检测,尤其适用于需低生物安全等级条件的场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neutralising antibodies are a candidate correlate of protection against SARS-CoV-2, typically they are measured using live virus neutralisation assays, however, these involve high containment work, are technically demanding and can have a long turn-around time. Therefore, surrogate assays are needed to support rapid screening and vaccine trials. Here, we assessed the Meso Scale Discovery (MSD) ACE2 inhibition assay (ACE2i) as a surrogate by comparing it with live virus neutralisation and total anti-spike IgG across ancestral, Delta, and Omicron SARS-CoV-2 spike proteins. Serum from 103 immunocompromised participants in the UK OCTAVE-DUO trial were analysed at baseline and 21 days post-booster. All assays detected significant post-vaccination increases, but micro-neutralisation assay (MNA) and ACE2i showed marked reductions against VoC, particularly Omicron and this was in contrast to IgG assays. The ACE2i assay offers a rapid, scalable, low containment surrogate for neutralisation to support the licensure of new SARS-CoV-2 vaccines and variant monitoring.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tipton T, Laidlaw S, Nguyen D, et al. ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation. Vaccine. 2025. PMID: 41422790. doi:10.1016/j.vaccine.2025.128123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。